1 / 19

Using Multiple Methods and Data Sources to Analyze Complex Cancer Research Portfolios

Using Multiple Methods and Data Sources to Analyze Complex Cancer Research Portfolios. Joshua Schnell Discovery Logic, A Thomson Reuters Business Co-Authors: Elizabeth Hsu, Jim Corrigan (NIH), Sandeep Patel, Lauren Taffe, Duane Williams (Discovery Logic). Data-driven portfolio management .

brigit
Download Presentation

Using Multiple Methods and Data Sources to Analyze Complex Cancer Research Portfolios

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Using Multiple Methods and Data Sources to Analyze Complex Cancer Research Portfolios Joshua Schnell Discovery Logic, A Thomson Reuters Business Co-Authors: Elizabeth Hsu, Jim Corrigan (NIH), Sandeep Patel, Lauren Taffe, Duane Williams (Discovery Logic)

  2. Data-driven portfolio management Technology Development Inventions Patents Biomarkers Clinical Development Clinical trials Biomarkers Approved Products FDA Approvals of Drugs, Devices and Biologics Public Health Impact Population Results Patient Outcomes Biomarkers Basic Research Findings Publications Citations Conference Proceedings Biomarkers The National Institutes of Health seeks to correlate the research and training it funds with subsequent public health impact.

  3. Robust, repeatable data linkages support portfolio analysis focused systems Technology Development Inventions Patents Biomarkers Clinical Development Clinical trials Biomarkers Approved Products FDA Approvals of Drugs, Devices and Biologics Public Health Impact Population Results Patient Outcomes Biomarkers Basic Research Findings Publications Citations Conference Proceedings Biomarkers NIH’s electronic Scientific Portfolio Assistant (e-SPA) currently provides linkages to early stage portfolio outputs and impact.

  4. Expanding the range of data-driven portfolio analysis Technology Development Inventions Patents Biomarkers Clinical Development Clinical trials Biomarkers Approved Products FDA Approvals of Drugs, Devices and Biologics Public Health Impact Population Results Patient Outcomes Biomarkers Basic Research Findings Publications Citations Conference Proceedings Biomarkers NCI’s Office of Science Planning and Assessment is conducting analyses of additional outputs such as cancer Biomarkers and FDA approved drugs.

  5. How has the NCI supported the development of cancer biomarkers? Background • Feasibility study to link funding data to breast cancer biomarkers • Thomson Reuters’ Integrity platform includes Biomarkers • High quality, manually curated data • Coverage of various cancer disease areas • Linkage to NCI funded projects through supporting reference material • Research publications considered by the Integrity editorial team as important for development of breast cancer biomarkers. • Research publications acknowledging NCI project support

  6. How has the NCI supported the development of cancer biomarkers? Methodology Patent Indication Biomarker Integrity Biomarkers Data 924 Biomarkers 2,040 Biomarkers with different validity statuses for different breast cancer indications (e.g. in situ ductal carcinoma) Validity Status Acknowledgement of NCI Support NIH Projects (IMPAC II) Publication

  7. How has the NCI supported the development of cancer biomarkers? Findings 66.7% 59.5% 32.0% 54.4% 32.4% SOURCES: Thomson Reuters Integrity, ScienceWire, NIH IMPAC II (May 2011)

  8. How has the NCI supported the development of cancer biomarkers? Findings, continued Grant Mechanisms Included R grants = 241 (181 are R01s) U and N grants = 100 P grants = 68 Z grants = 10 Training (F,K,L,T) = 35

  9. How has the NCI supported the development of cancer biomarkers? Portfolio Implications • Feasibility study has demonstrated: • The utility of linking NCI projects to biomarker outputs • The role of NCI support in breast cancer biomarker development • New portfolio management questions can now be asked, such as: • What mechanisms are most effective at supporting the various biomarker stage development? • What is the total funding investment made for biomarker development? • What diseases lack biomarkers and should be considered for targeted support?

  10. How has the NCI supported the development of FDA approved drugs? Background NCI Project [IMPACII] NDA-Listed Patent [USPTO Patent] Approved Drugs [FDA Orange Book] FDA products linked to NCI funding through acknowledgment in patents listed in the New Drug Application (NDA). Direct patent acknowledgements represent direct links to the NCI projects. Direct acknowledgements by NDA listed patents identified 6 FDA approved drugs linked to 6 NCI funded projects. Patent Acknowledgement of NCI Support SOURCES: Thomson Reuters Web of Science, MEDLINE, ScienceWire, The Patent Board, NIH IMPACII, FDA Orange Book, USPTO Issued Patents

  11. How has the NCI supported the development of FDA approved drugs? Methodology NCI Project [IMPACII] Publication [MEDLINE] NDA-Listed Patent [USPTO Patent] Approved Drugs [FDA Orange Book] • Links established through non-patent references found in the patents listed in the NDA. • High confidence, direct links include those with the same personnel and organization in: • NDA listed patent • Publication it cites and • NCI Project that funded the publication. • Automated approach identified high confidence, direct links: • 9 drugs linked to • 12 NCI funded projects. Non-Patent Reference List Patent Acknowledgement of NCI Support Acknowledgement of NCI Support SOURCES: Thomson Reuters Web of Science, MEDLINE, ScienceWire, The Patent Board, NIH IMPACII, FDA Orange Book, USPTO Issued Patents

  12. How has the NCI supported the development of FDA approved drugs? Findings This table lists 7 of the 12 projects identified as having shared both person and organization information. Orange highlights indicate drug-to-project links established only through non-patent references (no direct patent reference to these projects) ‡ P30CA16087 project was also identified as contributing to one of the breast cancer biomarkers SOURCES: Thomson Reuters Web of Science, MEDLINE, ScienceWire, The Patent Board, NIH IMPACII, FDA Orange Book, USPTO Issued Patents

  13. How has the NCI supported the development of FDA approved drugs? Portfolio Implications • This analysis has shown that: • Non-Patent Reference data can serve as a source for additional linkages to outputs like FDA approved drugs • Metadata about the outputs can be effectively used to identify high-confidence, direct links • Understanding NCI funding directly related to drug development helps to: • Measure late-stage impact of research funding on public health by enabling analysis of drug-specific impacts • Potentially identify areas where support is needed for particular indications or therapy targets

  14. What can be done when the portfolio to be analyzed is not associated with output data? • The International Cancer Research Partners includes 50 international funding agencies focused on cancer research who awarded over 36,000 research projects from 2006-2008. • Although some members have developed systems for tracking outputs arising from ICRP research awards, the partnership does not yet have a comprehensive system. • OSPA carried out a feasibility study of linking research publications in Thomson Reuters Web of Science to research projects in the ICRP portfolio.

  15. Publication Outputs Missing Because Award Codes Were Insufficient to Match • The feasibility study found that researchers were not acknowledging support by grant number (award code). • Total ICRP Awards • Awards Matched to WoS Publications • Percentage of Total ICRP Awards Matched to WoS Publications 5% 2% 10% 9% 1% 1%

  16. Additional Matching Methods for Increasing Publication Output Identification • Using Funding Agency Names • Successful for funding agencies whose portfolio is exclusively focused on cancer research (e.g. American Cancer Society), but not for broadly-focused portfolios (e.g. Wellcome Trust) • Using Principal Investigator Name SOURCES: Thomson Reuters Web of Science and ICRP

  17. Identifying Candidate ICRP members using ICRP-funded Publications Most Common Funders Most Common Cancer-specific Funders Most Common Non-government Funders

  18. Future development of outputs data for portfolio analysis • Improve data collection and automation of weighted linkages. • Establish data-driven linkages between funding and later stage research outputs and outcomes. • Enable portfolio analysis across a broad range of data sources and methodologies to reflect the broad range of research outputs.

  19. Acknowledgements • Biomarkers • NCI OSPA: James Corrigan, Elizabeth Hsu, Lawrence Solomon • Discovery Logic/Thomson Reuters: Sandeep Patel, Tina Brust • FDA Patent Analysis • NCI OSPA: James Corrigan, Elizabeth Hsu, Lawrence Solomon • Discovery Logic/Thomson Reuters: Duane Williams • The Patent Board: Kim Hamilton • ICRP • NCI OSPA: James Corrigan, Elizabeth Hsu, Lawrence Solomon, Samantha Finstad (AAAS Fellow) • Discovery Logic/Thomson Reuters: Sandeep Patel, Lauren Taffe

More Related